Click it and Unblock the Notifications
Latest Updates
-
Who Was Mithu Mukherjee? Veteran Bengali Actress Passes Away At 71 -
Ahmedabad Police Flag Fraud Risk Behind Viral 'Rent A Garba Partner' Ads -
Vidya Balan’s Jailer 2 Entry As Kantha: From Silk To Manjulika, A Look At Her Unconventional Roles -
Samay Raina Has Now Denied Dating Rumours With Two Women In Three Months -
Kareena Kapoor Turns 46: From Size Zero To Fine Lines, The ‘Daayra’ Actress Is Choosing To Age Without Apology -
The Emotional Side of Delayed Parenthood That We Don’t Talk About Enough -
World Alzheimer’s Day 2026: Why Early Diagnosis Matters And What This Year’s Theme Means -
When Is Navratri In 2026? Full Dates, Rituals, Colours, Significance, and Fasting Guide -
Vijay Sethupathi Confirms Maharaja 2, Hollywood Remake In The Works -
Dashavatara Vrat 2026: Everything To Know About Tithi, Rituals, Fasting And The Ten Forms Of Lord Vishnu
Corbevax Will Be Allowed As A Booster For Those Fully Vaccinated With Covishield Or Covaxin
Allowing Biological E's Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said.
The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above. India's first indigenously-developed RBD protein subunit vaccine, Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years.
"The National Technical Advisory Group on Immunisation (NTAGI) will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated with Covishield or Covaxin," a source told PTI.
The government advisory panel is also expected to review the trial data of the country's first quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, developed by the Serum Institute of India.
A separate HPV working group of the NTAGI had, on June 8, examined the vaccine's clinical trial data and usefulness for inclusion in the national immunisation programme, sources had said.
The recommendation of the Standing Technical Sub-Committee (STSC) of the NTAGI on reducing the gap between the second dose and the precaution dose of Covid vaccines from nine to six months may also be ratified at the meeting to be chaired by the Union health secretary. PTI PLB RC
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.
Continue with Google
